Novo Nordisk A/S
$ 39.63
-16.43%
23 Feb - close price
- Market Cap 210,863,309,000 USD
- Current Price $ 39.63
- High / Low $ 41.09 / 39.34
- Stock P/E 12.96
- Book Value 6.88
- EPS 3.66
- Next Earning Report 2026-05-06
- Dividend Per Share $11.70
- Dividend Yield 3.92 %
- Next Dividend Date 2026-04-08
- ROA 0.17 %
- ROE 0.61 %
- 52 Week High 89.43
- 52 Week Low 39.34
About
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Analyst Target Price
$54.05
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-03 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-04 | 2024-11-06 | 2024-08-07 | 2024-05-02 | 2024-01-31 | 2023-11-02 | 2023-08-10 | 2023-05-04 |
| Reported EPS | 6.04 | 4.5 | 5.96 | 6.53 | 6.34 | 6.12 | 0.66 | 0.83 | 0.71 | 0.73 | 0.67 | 0.63 |
| Estimated EPS | 5.9 | 4.24 | 6 | 6.07 | 6.12 | 5.92 | 0.7366 | 0.77 | 0.66 | 0.69 | 0.63 | 0.61 |
| Surprise | 0.14 | 0.26 | -0.04 | 0.46 | 0.22 | 0.2 | -0.0766 | 0.06 | 0.05 | 0.04 | 0.04 | 0.02 |
| Surprise Percentage | 2.3729% | 6.1321% | -0.6667% | 7.5783% | 3.5948% | 3.3784% | -10.3991% | 7.7922% | 7.5758% | 5.7971% | 6.3492% | 3.2787% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 4.94 |
| Currency | USD |
Previous Dividend Records
| Apr 2026 | Aug 2025 | Apr 2025 | Aug 2024 | Apr 2024 | Aug 2023 | Apr 2023 | Aug 2022 | Apr 2022 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-04-08 | 2025-08-26 | 2025-04-08 | 2024-08-26 | 2024-04-02 | 2023-08-29 | 2023-04-04 | 2022-08-23 | 2022-04-05 | None |
| Amount | $1.275101 | $0.584816 | $1.099206 | $0.5169016 | $0.92985 | $0.8835613 | $1.1887415 | $0.5835507 | $1.0360282 | $0.5570941 |
Next Dividend Records
| Dividend per share (year): | $11.70 |
| Dividend Yield | 3.92% |
| Next Dividend Date | 2026-04-08 |
| Ex-Dividend Date | 2026-03-30 |
Recent News: NVO
2026-02-23 17:48:39
Eli Lilly has strengthened its position in the obesity drug market following new developments. The company's Zepbound demonstrated superior weight loss efficacy compared to Novo Nordisk's experimental drug CagriSema, and Lilly also announced a new, more convenient device for Zepbound. This news led to a significant drop in Novo Nordisk's shares while Eli Lilly's stock saw an increase.
2026-02-23 17:45:52
European markets opened with notable shifts as Novo Nordisk shares tumbled over 15% due to a clinical trial setback for its obesity treatment, wiping out significant market cap gains. Concurrently, Finnish quantum-computing firm IQM announced intentions to go public via a SPAC merger valuing it at $1.8 billion. Meanwhile, fresh trade tariff uncertainties arose between the UK and US, and France's government faced another no-confidence motion over a new energy law.
2026-02-23 14:27:00
Novo Nordisk's next-generation weight-loss drug CagriSema performed less effectively than Eli Lilly's Zepbound in a recent trial, hindering Novo Nordisk's efforts in the obesity drug market. This setback is prompting analysts to suggest that investor focus may now shift to Novo Nordisk's M&A strategy, with recommendations for acquisitions in adjacent therapy areas. Analysts believe that Eli Lilly's Zepbound is set to remain the market leader for the foreseeable future.
2026-02-23 13:09:11
Novo Nordisk's next-generation obesity drug, CagriSema, failed to prove non-inferiority to Eli Lilly's tirzepatide in weight loss, causing Novo Nordisk's shares to drop significantly. Patients on CagriSema lost an average of 23% body weight compared to 25.5% for those on tirzepatide. This setback comes as competition in the obesity drug market intensifies and Lilly's treatments gain market share over Novo's existing drugs.
2026-02-23 12:45:52
Novo Nordisk's stock declined after its experimental obesity drug, CagriSema, failed to meet a primary endpoint in a trial, while rival Eli Lilly saw its stock rise. Netflix shares also dropped due to political pressure from President Trump. Conversely, Domino's Pizza exceeded sales expectations, and Arcellx surged following an acquisition announcement by Gilead Sciences.
2026-02-23 12:33:48
Arcellx surged after Gilead Sciences announced its acquisition for $7.8 billion. Novo Nordisk fell due to a weight-loss drug trial setback, while Eli Lilly rose. Domino's Pizza, and Fortune Brands Innovations saw gains, while VF Corp, several software stocks, and airline stocks experienced declines.
